country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Referencia número: HY-13976A

Copy Link Print Information

PRL-8-53

PRL-8-53 is an orally active, blood-brain barrier-permeable benzoate derivative with potent spasmolytic activity and central nervous system regulatory activity. PRL-8-53 acts on dopamine, serotonin and cholinergic-related targets, enhances dopamine activity, partially inhibits serotonin function and elicits cholinergic responses, thereby maintaining neurotransmitter balance in the central nervous system. PRL-8-53 improves learning ability, short-term memory and long-term memory in animals. PRL-8-53 can be used in central nervous system-related research.

Para uso exclusivo en investigación. No vendemos a pacientes.

No. CAS: 51352-87-5
Fòrmula: C₁₈H₂₂ClNO₂
Peso molecular:319.83

Almacenamiento:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (266 KB)

PRL-8-53 Chemical Structure

No. CAS: 51352-87-5

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- In Vitro
- In Vivo
Chemical Information
Pureza y Documentación
Referencias
Calculators
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

In Vitro

PRL-8-53 modulates dopamine, serotonin and cholinergic targets, potentiates dopamine activity, partially inhibits serotonin function and triggers cholinergic responses in experimental animals^[1]^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

PRL-8-53 (p.o.) exhibits low oral toxicity in mice and depresses motor activity with an ED₅₀ of 160 mg/kg, without inducing stereotypic behavior at doses up to 200 mg/kg^[1].
PRL-8-53 does not alter d-amphetamine stimulant effects or avoidance rate in rats at tested doses, reverses reserpine-induced catatonia and ptosis, and does not induce stereotypic behavior at doses up to 200 mg/kg^[1].
PRL-8-53 does not significantly alter blood pressure in normotensive dogs at doses up to 8 mg/kg^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

No. CAS 51352-87-5
Peso molecular 319.83
Fòrmula C₁₈H₂₂ClNO₂
SMILES

O=C(C1=CC=CC(CCN(CC2=CC=CC=C2)C)=C1)OC.Cl
Envío

Room temperature in continental US; may vary elsewhere.
Almacenamiento

Please store the product under the recommended conditions in the Certificate of Analysis.

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (266 KB)
SDS (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Hansl NR, et al. PRL-8-53: enhanced learning and subsequent retention in humans as a result of low oral doses of new psychotropic agent. Psychopharmacology (Berl). 1978;56(3):249-253. [Content Brief]

[2]. Hansl NR. A novel spasmolytic and CNS active agent 3-(2-benzylmethylaminoethyl) benzoic acid methyl ester hydrochloride. Experientia. 1974 Mar 01;30:271-272.

Calculators

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Obtener un presupuesto En stock

Other size

Obtener un presupuesto